Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · IEX Real-Time Price · USD

4.070

-0.030 (-0.73%)

At close: Jul 19, 2024, 4:30 PM

4.040

-0.030 (-0.74%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Design Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0	0	0.23	0.83
Revenue Growth (YoY)	-	-	-	-	-72.90%	-
Gross Profit	0	0	0	0	0.23	0.83
Selling, General & Admin	19.81	21.13	18.98	11.05	2.5	1.09
Research & Development	51.13	57.06	48.61	24.78	6.06	1.65
Operating Expenses	70.94	78.19	67.59	35.83	8.56	2.74
Operating Income	-70.94	-78.19	-67.59	-35.83	-8.33	-1.91
Other Expense / Income	-12.27	-11.33	-4.29	-0.3	-0.05	0.14
Pretax Income	-58.67	-66.86	-63.31	-35.53	-8.28	-2.05
Net Income	-58.67	-66.86	-63.31	-35.53	-8.28	-2.05
Shares Outstanding (Basic)	56	56	56	46	16	15
Shares Outstanding (Diluted)	56	56	56	46	16	15
Shares Change	1.04%	0.50%	21.27%	190.80%	2.08%	-
EPS (Basic)	-1.05	-1.19	-1.14	-0.77	-0.52	-0.13
EPS (Diluted)	-1.05	-1.19	-1.14	-0.77	-0.52	-0.13
Free Cash Flow	-53.94	-58.82	-52.2	-30.92	-8.75	-0.14
Free Cash Flow Per Share	-0.95	-1.05	-0.94	-0.67	-0.55	-0.01
Gross Margin	-	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-	-3685.84%	-228.78%
Profit Margin	-	-	-	-	-3663.72%	-245.44%
Free Cash Flow Margin	-	-	-	-	-3869.47%	-16.67%
EBITDA	-58.1	-66.29	-62.84	-35.39	-8.28	-2.05
EBITDA Margin	-	-	-	-	-3661.50%	-245.44%
Depreciation & Amortization	0.58	0.57	0.47	0.15	0.01	0
EBIT	-58.67	-66.86	-63.31	-35.53	-8.28	-2.05
EBIT Margin	-	-	-	-	-3663.72%	-245.44%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).